



FRAMEWORK AGREEMENT 3-III DGD-ITM 2014-2016

"1.23"

"STRATEGIC NETWORK TROPICAL AND NEGLECTED DISEASES"

CONTRACT BETWEEN

The **Institute of Tropical Medicine**, Antwerp, Belgium.

Hereinafter referred to as « **ITM** »

Represented by Prof. Dr. Bruno Gryseels, Director,

and

The **Instituto de Medicina Tropical "Alexander von Humboldt"**, Lima, Peru

Hereinafter referred to as « **IMTAvH** »

Represented by Dr. Juan Miyahira Arakaki, Director.

and

The **"Universidad de las Fuerzas Armadas"**, Quito, Ecuador

Hereinafter referred to as « **ESPE** »

Represented by Grab. Roque Moreira, Rector

Article 1: Definition and limitation

- 1.1. This Contract defines the conditions of the collaboration between ITM, the Instituto de Medicina Tropical "Alexander von Humboldt" and the "Universidad de la Fuerzas Armadas" (hereinafter also referred to as "Parties"), for the execution of the project "Strategic Network Tropical and Neglected Diseases" (hereinafter referred to as the "Project"). This project is part of the third Multi-annual Programme of the Framework Agreement Phase 3, 2014-2016 or FA3-III) between ITM and the Belgian Directorate-General for Development Co-operation (DGD) (hereinafter referred to as "the Programme"), as approved The programme results, activities and budgets will remain subject to the agreement with DGD and possible amendments to that agreement.



Article 2: Objectives

- 2.1 The objective of this contract is to give Support grants to junior researchers. The protocol of the project figures in Annex 1. The partners will engage themselves in executing the project in a reliable manner according to their means and capacities.
- 2.2. No substantial change in objectives, planned activities, obligations or budgets can be made without prior approval of the ITM.

Article 3: Management

- 3.1. The Parties commit themselves to carry out this Project in faithful collaboration according to their respective means and to the best of their abilities.
- 3.2. The Parties are jointly responsible for fulfilling the objectives and expected results described in the Plan. The specific contribution to the Project of each Party is defined in Annex I.
- 3.3. No right or obligation resulting from this contract can be transferred to a third party without prior written agreement between the Parties.
- 3.4. All written or oral information obtained during the preparation, execution or follow-up of this Project by either Party or one of its employees, consultants, trainees or students will be kept confidential and will not be disseminated without prior written agreement between the Parties.
- 3.5. Each Party will adhere to international and national principles of ethics and integrity, in research as well as in clinical practice and community action, in the execution of this Project. All studies involving humans will be submitted to and approved by the relevant institutional and national ethical committees and to the competent regulatory authorities.
- 3.6. The intellectual property rights (IPR) on the results of this Project will be jointly owned by ITM and IMTAvH/ESPE. Use of these results by one of the parties for internal scientific research or educational purposes is permitted. In case of discussion, the ITM regulations on IPR (attached in annex III) will be used as reference.
- 3.7. Other exploitation rights on the results of this Project, including commercial as well as non-commercial applications, patents, copyrights and other protective procedures will be subject to a separate agreement between the Parties.
- 3.8. Scientific publications by either Party, resulting from or based on the Project must mention DGD as donor agency, and reflect the true contribution of each scientist involved. Each such publication will be submitted for approval to the involved scientists of the other Party. If no objection is raised within two months by the second Party, then the first Party can proceed with the publication.

